These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

812 related items for PubMed ID: 19417153

  • 1. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D.
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [Abstract] [Full Text] [Related]

  • 2. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J, Brewer KJ, Hoffman A, Lusby K, Lazar AJ, Pollock RE, Lev D.
    Mol Cancer Ther; 2012 Aug; 11(8):1758-69. PubMed ID: 22848094
    [Abstract] [Full Text] [Related]

  • 3. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, Laurendeau I, Lantieri L, Wolkenstein P, Vidaud M, Pasmant E, Chapuis N, Parfait B.
    Oncotarget; 2016 Jun 14; 7(24):35753-35767. PubMed ID: 26840085
    [Abstract] [Full Text] [Related]

  • 4. Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
    Aggarwal S, John S, Sapra L, Sharma SC, Das SN.
    Cancer Chemother Pharmacol; 2019 Mar 14; 83(3):451-461. PubMed ID: 30519710
    [Abstract] [Full Text] [Related]

  • 5. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
    Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.
    Cancer Res; 2009 Apr 15; 69(8):3520-8. PubMed ID: 19351820
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y, Oda Y.
    Clin Cancer Res; 2013 Jan 15; 19(2):450-61. PubMed ID: 23209032
    [Abstract] [Full Text] [Related]

  • 7. Akt and autophagy cooperate to promote survival of drug-resistant glioma.
    Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA.
    Sci Signal; 2010 Nov 09; 3(147):ra81. PubMed ID: 21062993
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
    Chen G, Chen SM, Wang X, Ding XF, Ding J, Meng LH.
    J Biol Chem; 2012 Apr 06; 287(15):12132-41. PubMed ID: 22337890
    [Abstract] [Full Text] [Related]

  • 9. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec 06; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 10. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
    Hu X, Xia M, Wang J, Yu H, Chai J, Zhang Z, Sun Y, Su J, Sun L.
    Biomed Pharmacother; 2020 Sep 06; 129():110397. PubMed ID: 32585451
    [Abstract] [Full Text] [Related]

  • 11. Arctigenin Triggers Apoptosis and Autophagy via PI3K/Akt/mTOR Inhibition in PC-3M Cells.
    Sun BL, Cai EB, Zhao Y, Wang Y, Yang LM, Wang JY.
    Chem Pharm Bull (Tokyo); 2021 May 01; 69(5):472-480. PubMed ID: 33627540
    [Abstract] [Full Text] [Related]

  • 12. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.
    Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond AL, Powell NM, Collins MH, Rizvi T, Moertel CL, Ratner N, Largaespada DA.
    Oncotarget; 2014 Mar 30; 5(6):1502-14. PubMed ID: 24681606
    [Abstract] [Full Text] [Related]

  • 13. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, Yang T, Chen XW, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Mar 30; 9():1555-84. PubMed ID: 25792811
    [Abstract] [Full Text] [Related]

  • 14. The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve sheath tumor cells.
    Kohli L, Kaza N, Lavalley NJ, Turner KL, Byer S, Carroll SL, Roth KA.
    Neuro Oncol; 2012 Mar 30; 14(3):266-77. PubMed ID: 22259051
    [Abstract] [Full Text] [Related]

  • 15. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
    Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, Burrell K, Croul S, Gutmann DH, Guha A.
    Int J Cancer; 2010 Jan 15; 126(2):563-71. PubMed ID: 19634141
    [Abstract] [Full Text] [Related]

  • 16. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.
    J Surg Res; 2012 Aug 15; 176(2):542-8. PubMed ID: 22261591
    [Abstract] [Full Text] [Related]

  • 17. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
    Schulte A, Ewald F, Spyra M, Smit DJ, Jiang W, Salamon J, Jücker M, Mautner VF.
    Int J Mol Sci; 2020 Feb 24; 21(4):. PubMed ID: 32102484
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells.
    Kim KY, Park KI, Kim SH, Yu SN, Park SG, Kim YW, Seo YK, Ma JY, Ahn SC.
    Int J Mol Sci; 2017 May 18; 18(5):. PubMed ID: 28524116
    [Abstract] [Full Text] [Related]

  • 19. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D, Brown VI, Grupp SA, Teachey DT.
    Paediatr Drugs; 2012 Oct 01; 14(5):299-316. PubMed ID: 22845486
    [Abstract] [Full Text] [Related]

  • 20. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N.
    Mol Cancer Ther; 2010 Apr 01; 9(4):963-75. PubMed ID: 20371718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.